Alzheimer’s disease develops slowly, over several years. It is thought to be a disease of the modern, unhealthy lifestyle. Though Alzheimer’s is commonly diagnosed in people over 65 years old, many people nowadays start to experience signs of cognitive decline at a younger age. Read on to learn about the signs & symptoms, diagnostic tools, and conventional treatment options.
You may have landed here from one of our posts from the Alzheimer’s series. If so, you know about the lifestyle and genetic factors that may underlie Alzheimer’s, as well as the ways in which you can naturally prevent and improve this disease.
In this post, you’ll get a run-through of the basics: the signs and symptoms of Alzheimer’s, diagnosis, progression, and more.
Alzheimer’s disease (AD) is a progressive degenerative brain disease. That is: Alzheimer’s gets worse with time. The brain is thought to undergo small changes decades (20+ years) before the first symptoms show .
Only after years of these incremental brain changes do individuals notice symptoms, such as memory loss and other cognitive problems .
With time, the damage becomes pronounced enough to cause symptoms. As the damage progresses, symptoms increase and start to interfere with daily functioning. At this stage, a person is said to have dementia due to Alzheimer’s disease [1, 2].
Alzheimer’s can damage neurons in other parts of the brain, such as the areas that control movement. Activities that used to be central to a person’s identity, such as going to family events or physical activity, are often no longer possible at this stage [1, 2].
Ultimately, neurons in parts of the brain that handle basic bodily functions, such as walking and swallowing, are affected. People in this final stage of AD require constant care, and eventually, the person afflicted dies from the disease .
About 95% of Alzheimer’s cases are so-called “late-onset” or “sporadic” type, usually diagnosed in people aged 65 years or older. The remaining 5% of cases are termed “early-onset” or “familial Alzheimer’s Disease” and are due to rare genetic mutations. In early-onset Alzheimer’s, symptoms normally set in from age 30-65 .
In this series, we will mainly discuss the late-onset form of Alzheimer’s disease.
Currently, there are 40-50 million cases of dementia worldwide. That number is increasing by 1 every 3 seconds, so that in 20 years the number of cases will be doubled .
The global cost of dementia was more than $800 million in 2015 and expected to reach $2 trillion by 2050. Low-income countries suffer the fastest growth of cases, more than double that of high-income countries .
More women than men (27 vs 17 million) had dementia in 2016, and dementia was the fifth leading cause of death globally, accounting for 2.4 million deaths .
An estimated 28 million years of life and productivity were lost due to dementia worldwide from 1990 to 2016. Of these, 6 million could be attributed to preventable risk factors such as obesity, high blood sugar, and smoking .
At this stage, the brain and cerebrospinal fluid undergo measurable changes (known as biomarkers), but symptoms are not yet noticeable. This stage may begin decades before any memory loss. Additionally, not everyone who experiences these brain changes will go on to develop the disease .
At this stage, people undergo both measurable brain changes (biomarkers) and experience symptoms of cognitive impairment. The decline in thinking abilities may be noticeable to friends or family, but it will remain unnoticeable to someone who doesn’t know the person well .
About 15-20% of people over 65 have mild cognitive impairment and up to 38% go on to develop dementia .
At this third stage, noticeable memory, thinking, and behavioral problems become evident, along with characteristic brain damage. The cognitive impairment is severe enough to interfere with daily functioning .
While the dementia is still mild, patients may be able to drive or work independently. However, moderate dementia causes difficulties with daily tasks such as bathing or dressing. Incontinence and personality changes may also arise. When dementia becomes severe, patients are likely to require constant care .
People aged 65+ survive an average of 4-8 years after being diagnosed with AD. Of the years they live with AD, people will spend an average of 40% in the severe stage, much of the time in a nursing home. At age 80, around 75% of people with AD live in a nursing home compared with only 4 percent of the general population .
Memory loss that interferes with daily functioning is the most common symptom of Alzheimer’s disease (AD), especially in the early stages when dementia is mild .
Since AD causes a slow but progressive decline in memory and thinking ability, people who are afflicted may experience a range of cognitive symptoms, including all of the following .
- Forgetting important dates or events, asking for the same information repeatedly, and increasingly needing to rely on memory aids (e.g. note-taking) or family members for remembering.
- Not being able to follow a plan or work with numbers.
- Having trouble following a recipe, keeping track of payments, or counting change.
- Having concentration issues, and taking longer than usual to accomplish things.
- Finding it hard to complete daily tasks, such as driving to a familiar location, managing a budget, or remembering the rules of a specific game.
- Losing track of dates, seasons, and the passage of time.
- Having trouble understanding something if it is not happening immediately.
- Forgetting where you are or how you got there.
- Having difficulty reading, judging distance, and determining color or contrast (enough to interfere with tasks such as driving).
- Having trouble following a conversation, stopping in the middle of a conversation, repeating yourself, or struggling with vocabulary and finding the right words.
- Putting things in unusual places, losing things, and being unable to retrace your steps to find them again.
- Sometimes, you may accuse others of stealing because you forgot that you misplaced an item.
- Showing poor judgment or decision-making, for example, when dealing with money.
- Paying less attention to grooming or keeping yourself clean.
- Withdrawing from hobbies, social activities, work projects or sports.
- You may also avoid socializing because of the changes you are experiencing.
- Becoming confused, suspicious, depressed, fearful, or anxious.
- Getting easily upset at home, at work, with friends or in places where you are out of your comfort zone.
Moderate stages show increased functional impairment and a lack of independence in handling complicated tasks. Patients consistently have difficulty remembering new information, often become disoriented, and are unable to recognize close family members .
In the most severe stages, patients ultimately develop a severe loss of mental function due to brain degeneration. All patients are completely dependent on a caregiver and can only communicate with simple words or phrases .
There is no definitive biological test that can diagnose Alzheimer’s disease at present. Doctors will, therefore, use other tools to diagnose AD, including :
- Taking a medical and family history, including whether anyone in a family had psychiatric disorders or changes in cognitive function or behavior.
- Asking family members about the changes in thinking, cognitive skills, and behavior.
- Conducting cognitive tests and physical and neurologic examinations.
- Doing blood tests and brain scans to rule out other potential causes of dementia symptoms, such as a tumor or certain vitamin deficiencies.
- Using brain scans to find out if the individual has high levels of beta-amyloid proteins; normal levels would suggest AD is not the cause of dementia.
A biomarker is a measurable biological change that can confirm the presence or absence of a disease. For example, high blood sugar is a biomarker of diabetes. Some potential biomarkers that are being studied right now for Alzheimer’s disease (AD) are [1, 9]:
- High levels of beta-amyloid and tau proteins in the brain as shown on PET scans; alternatively, high beta-amyloid levels in the blood or brain fluid
- Degree of glucose metabolism in the brain as shown on PET scans (poor glucose metabolism in the brain may indicate AD)
- Fibrinogen gamma-chain (FGG) blood levels, along with anandamide and 2 other blood markers
- Protein panel levels combined with APOE ε4 allele testing (and complement C3 blood levels)
- Special lipid panel levels, including phosphatidylcholines and acylcarnitines in the blood
At this point, the experts cannot rely on biomarkers alone to diagnose AD; they are not reliable enough. For example, a person may have these biomarkers and not have symptoms of dementia. Others may not have these biomarkers and have dementia.
We may discover more accurate biomarkers in the future. Combining genetic tests and blood tests that measure gene expression (such as proteinomics and miRNA signatures) is the most promising approach .
Although doctors can almost always determine if a person has dementia, it may be difficult to identify the exact cause.
Alzheimer’s disease is the most common cause of dementia, accounting for 80% of cases. Getting a correct diagnosis is key, as it ensures you’ll receive the right treatment. Other forms of dementia are outlined below .
Vascular dementia accounts for 5-10% of cases. It is caused by damage to brain cells due to blockage of blood vessels or bleeding in the brain .
While memory loss is the hallmark of Alzheimer’s disease, impaired judgment and reduced decision-making ability are more likely to appear first in vascular dementia. There may also be problems with motor function, such as slow gait or poor balance .
Lewy body is a form of dementia that is due to clumps of the protein alpha-synuclein inside brain cells. Compared with Alzheimer’s disease, people with Lewy body dementia are more likely to experience sleep disturbance, hallucinations, poor balance, or movement problems. Like vascular dementia, Lewy body dementia accounts for 5-10% of cases .
Initially, doctors considered it rare for people to have more than one type of dementia, but recent studies show that over 50% of patients with Alzheimer’s disease are likely to suffer from other forms of dementia as well. The risk of having mixed forms of dementia is highest for people older than 85 years .
Not everyone who experiences symptoms of dementia has Alzheimer’s disease, or other forms of dementia for that matter. Several disorders can mimic the symptoms of the early stages of dementia. Some common causes of dementia-like symptoms are :
- Sleep apnea
- Side effects of medications
- Brain fog
- Thyroid disease
- Nutrient deficiencies, and
- Excessive alcohol consumption
Science has yet to identify the underlying Alzheimer’s disease-triggering pathway that could be targeted with conventional treatment. Pharmaceutical treatments today only target the symptoms and replenish the levels of neurotransmitters to improve patients’ quality of life.
Acetylcholine is the most important neurotransmitter for attention, learning, and memory. A drop in its activity – due to a loss of neurons or the connections between them – impairs cognitive function .
In Alzheimer’s disease, the so-called cholinergic neurons that use acetylcholine get damaged and destroyed. Acetylcholine transporters may also stop working, making it harder for acetylcholine to get to its job in the first place [11, 12].
Both donepezil and galantamine, described below, are acetylcholinesterase inhibitors.
In a review of 30 studies involving more than 8k patients with AD, donepezil was found to be mildly effective at improving cognitive function and daily functioning .
A review study of more than 4k patients with AD concluded that galantamine significantly improves cognitive function, but not overall daily functioning. In a trial of 1500 patients with AD and heart disease, galantamine also improved attention and cognitive function [14, 15].
In a trial of 36 patients with AD who had not previously responded to donepezil, galantamine significantly improved their ability to make decisions, and neuropsychiatric symptoms (e.g. apathy, irritability, movement). The reason galantamine worked better may be because of its ability to improve the function of nicotinic receptors in the frontal lobe .
Glutamate is the main excitatory neurotransmitter in the brain. Where GABA calms the brain, glutamate activates it. Ideally, GABA and glutamate should be in balance. Excess glutamate over-stimulates brain cells until can no longer handle the stimulation – and they die. This is one of the characteristics of Alzheimer’s disease .
Memantine is a medication that blocks NMDA receptors, which glutamate acts upon. Memantine protects neurons from the toxic effects of excess glutamate release (excitotoxicity) without disrupting normal neuronal function .
Aducanumab is a human monoclonal antibody that reacts with and clears beta-amyloid proteins. In a trial of 165 patients with AD, intravenous infusions of aducanumab significantly reduced beta-amyloid plaque deposits in patient’s brains. The drug also slowed the patient’s decline in cognitive function. Aducanumab is currently undergoing a phase 3 trial .
Alzheimer’s disease is the number one cause of dementia worldwide. Brain changes occur decades before the first symptoms become noticeable. As the disease progresses, more brain cells suffer damage. This causes confusion, extreme forgetfulness, and personality changes.
In the late stages of the disease, people need to be under constant medical care. Doctors diagnose Alzheimer’s based on overall symptoms, family history, and brain scans. New tests might make early and more accurate diagnosis a reality, based on blood markers and genes.
Conventional Alzheimer’s disease treatment includes cholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine) and glutamate-blockers (Memantine).
If you haven’t read through the other parts, head on over to:
- In part 2, where we explore the possible causes and risk factors of Alzheimer’s. Including the modern lifestyle.
- In part 3, where you will learn how to naturally treat or prevent Alzheimer’s through diet, supplements, and lifestyle choices.
- In part 4, where we go over emerging remedies to see if there is, indeed, a natural cure for this disease